Finlands Akademi
Finansieringsbeslut
 
Namn Würtz, Peter
Organisation HY
Projektets titel Metabolomic signatures of cardiovascular risk factors and pharmacotherapy
Beslutnr 312477
Beslutsdatum 25.05.2016
Finansieringsperiod 01.01.2017 - 31.12.2017
Finansiering 88 266
WebFOCUS Report
Beskrivning av projektet
Heart disease is the leading major cause of death worldwide. A better molecular understanding of the underlying risk factors may improve the early prevention and identify new options for treatment. Here, we study cardiovascular disease progression using a new screening technology developed at University of Oulu to profile 228 metabolic measures per blood sample. This provides an detailed snapshot of a person’s health state. Some of the biomarkers measured by the new screening technology (e.g. amino acids and fatty acids) reflect the risk for future heart disease; however, the mechanisms behind are not understood. The aim here is to uncover the role of the novel biomarkers in the development of heart disease. The blood screening has been measured from >100,000 volunteers whose health status and genetic makeup is known. The large-scale data analyses will clarify the complex causes of heart disease and stroke, and benefit the development of new drugs to prevent the disease processes.